KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q4 2025 value amounting to $6.1 million.

  • CRISPR Therapeutics AG's Other Non-Current Liabilities rose 7833.91% to $6.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $6.1 million, marking a year-over-year increase of 7833.91%. This contributed to the annual value of $6.1 million for FY2025, which is 7833.91% up from last year.
  • As of Q4 2025, CRISPR Therapeutics AG's Other Non-Current Liabilities stood at $6.1 million, which was up 7833.91% from $5.3 million recorded in Q3 2025.
  • Over the past 5 years, CRISPR Therapeutics AG's Other Non-Current Liabilities peaked at $8.7 million during Q2 2021, and registered a low of $958000.0 during Q4 2023.
  • In the last 5 years, CRISPR Therapeutics AG's Other Non-Current Liabilities had a median value of $5.4 million in 2023 and averaged $5.4 million.
  • Per our database at Business Quant, CRISPR Therapeutics AG's Other Non-Current Liabilities plummeted by 8395.04% in 2023 and then surged by 25949.9% in 2024.
  • Over the past 5 years, CRISPR Therapeutics AG's Other Non-Current Liabilities (Quarter) stood at $7.3 million in 2021, then fell by 18.67% to $6.0 million in 2022, then crashed by 83.95% to $958000.0 in 2023, then skyrocketed by 259.5% to $3.4 million in 2024, then soared by 78.34% to $6.1 million in 2025.
  • Its Other Non-Current Liabilities was $6.1 million in Q4 2025, compared to $5.3 million in Q3 2025 and $4.5 million in Q2 2025.